Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by Rock Springs Capital Management LP

Rock Springs Capital Management LP grew its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,080,963 shares of the company's stock after buying an additional 17,053 shares during the quarter. Rock Springs Capital Management LP owned 1.89% of Structure Therapeutics worth $29,316,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its stake in shares of Structure Therapeutics by 673.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after purchasing an additional 3,549 shares during the period. Capital International Investors raised its position in Structure Therapeutics by 6.8% in the 4th quarter. Capital International Investors now owns 1,619,081 shares of the company's stock valued at $43,909,000 after purchasing an additional 103,059 shares in the last quarter. Marshall Wace LLP grew its position in shares of Structure Therapeutics by 339.6% during the fourth quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock worth $15,817,000 after buying an additional 450,531 shares in the last quarter. Mariner LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth approximately $665,000. Finally, Barclays PLC raised its holdings in Structure Therapeutics by 42.6% in the fourth quarter. Barclays PLC now owns 115,671 shares of the company's stock valued at $3,138,000 after acquiring an additional 34,533 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Up 0.4 %

NASDAQ:GPCR traded up $0.09 during trading hours on Friday, reaching $23.74. 731,787 shares of the company's stock were exchanged, compared to its average volume of 913,938. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -32.08 and a beta of -1.35. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The company has a 50-day moving average of $20.17 and a 200 day moving average of $27.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on GPCR shares. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target on the stock. William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has a consensus rating of "Buy" and an average target price of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.